Literature DB >> 16177098

Regulation of rat basophilic leukemia-2H3 mast cell secretion by a constitutive Lyn kinase interaction with the high affinity IgE receptor (Fc epsilon RI).

Becky M Vonakis1, Scott P Gibbons, Masashi J Rotté, Elizabeth A Brothers, Seok C Kim, Kristin Chichester, Susan M MacDonald.   

Abstract

Signaling through the high affinity IgE receptor is initiated by noncovalently associated Lyn kinase, resulting in the secretion of inflammatory mediators from mast cells. A fraction of the total cellular Lyn is associated via its N-terminal unique domain with the cytoplasmic domain of the Fc epsilonRI beta subunit before receptor aggregation. In the current study, we stably transfected the unique domain of Lyn into rat basophilic leukemia-2H3 mast cells and examined the consequences on Fc epsilonRI-induced signal transduction and mediator secretion to further define the role of the unique domain of Lyn in mast cell secretion. Tyrosine phosphorylation of Fc epsilonRI beta and gamma subunits was partially inhibited in the Lyn unique domain transfectants after Ag stimulation. Ag stimulation of Lyn unique domain transfectants was accompanied by enhanced phosphorylation of MEK and ERK-2, which are required for leukotriene C4 (LTC4) release, and production of LTC4 was increased 3- to 5-fold, compared with cells transfected with vector alone. Conversely, tyrosine phosphorylation of the adaptor protein Gab2, which is essential for mast cell degranulation, was inhibited after Ag stimulation of Lyn unique domain transfectants, and Ag-induced release of histamine was inhibited up to 48%. In rat basophilic leukemia-2H3 cells, Lyn thus plays a dual role by positively regulating Fc epsilonRI phosphorylation and degranulation while negatively regulating LTC4 production. This study provides further evidence that the constitutive interaction between the unique domain of Lyn and the Fc epsilonRI beta subunit is a crucial step in the initiation of Fc epsilonRI signaling and that Lyn is limiting for Fc epsilonRI-induced secretion of inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177098     DOI: 10.4049/jimmunol.175.7.4543

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha 9/alpha 10-nicotinic receptors.

Authors:  Neerad C Mishra; Jules Rir-sima-ah; R Thomas Boyd; Shashi P Singh; Sravanthi Gundavarapu; Raymond J Langley; Seddigheh Razani-Boroujerdi; Mohan L Sopori
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

2.  Down-regulation of protein-tyrosine phosphatases activates an immune receptor in the absence of its translocation into lipid rafts.

Authors:  Petr Heneberg; Lubica Dráberová; Monika Bambousková; Petr Pompach; Petr Dráber
Journal:  J Biol Chem       Date:  2010-02-15       Impact factor: 5.157

3.  A new class of human mast cell and peripheral blood basophil stabilizers that differentially control allergic mediator release.

Authors:  Sarah K Norton; Anthony Dellinger; Zhiguo Zhou; Robert Lenk; Darren Macfarland; Becky Vonakis; Daniel Conrad; Christopher L Kepley
Journal:  Clin Transl Sci       Date:  2010-08       Impact factor: 4.689

Review 4.  Regulation of mast cell responses in health and disease.

Authors:  Alasdair M Gilfillan; Michael A Beaven
Journal:  Crit Rev Immunol       Date:  2011       Impact factor: 2.214

5.  Effects of IL-3 and SCF on Histamine Production Kinetics and Cell Phenotype in Rat Bone Marrow-derived Mast Cells.

Authors:  Haneul Nari Lee; Chul Hwan Kim; Gwan Gyu Song; Sung-Weon Cho
Journal:  Immune Netw       Date:  2010-02-28       Impact factor: 6.303

Review 6.  New insights on mast cell activation via the high affinity receptor for IgE.

Authors:  Juan Rivera; Nora A Fierro; Ana Olivera; Ryo Suzuki
Journal:  Adv Immunol       Date:  2008       Impact factor: 3.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.